Management of HCV patients with cirrhosis with direct acting antivirals

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 38-45

  Boccaccio, Vincenzo ^a   Bruno, Savino ^a  

^a AO Fatebenefratelli e Oftalmico ^*  (Italy)

Author keywords

Boceprevir; Direct acting antivirals; Faldaprevir; HCV related cirrhosis; Hepatitis C virus; Simeprevir; Sofosbuvir; Sustained virological response; Telaprevir

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; CANCER MORTALITY; CANCER RISK; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; THERAPY EFFECT;

BOCEPREVIR; DIRECT ACTING ANTIVIRALS; FALDAPREVIR; HCV-RELATED CIRRHOSIS; HEPATITIS C VIRUS; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGICAL RESPONSE; TELAPREVIR;

ALGORITHMS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LIVER CIRRHOSIS; OLIGOPEPTIDES; PROLINE; SULFONAMIDES; THIAZOLES; TIME FACTORS; URIDINE MONOPHOSPHATE;

EID: 84890868950     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12391     Document Type: Review

References (36)

1. Bourlière M, Wendt A, Fontaine H, et al. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int 2013; 33(Suppl. 1): 46-55.
2. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302.
3. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.
4. Qamar AA, Grace ND, Groszmann RJ, et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008; 47: 153-9.
5. Gomez EV, Rodriguez YS, Bertot LC, et al. J Hepatol 2013; 58: 434-44.
6. Bruno S, Saibeni S, Bagnardi V, et al. Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. Am J Gastroenterol 2013; 108: 1112-22.
7. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
8. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
9. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
10. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.
11. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
12. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
13. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.
14. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
15. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl. 1): 93-104.
16. Poordad F, McCone J Jr, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
17. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
18. Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: PROVIDE study interim results. EASL 2012 A 204.
19. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
21. Bruno S, Mangia A. Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era. Dig Liver Dis 2013; 45: 356-61.
22. Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013; 58: 479-87.
23. Vierling JM, Zeuzem S, Poordad F, et al. Safety & Efficacy of Boceprevir/Peginterferon/Ribavirin for HCV G1 Compensated Cirrhotics: Meta-Analysis of 5 Trials. EASL 2013. Abstract 1430.
24. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
25. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2013; Jun 28. doi: 10.1002/hep.26602.
26. Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). EASL 2013. Abstract 60.
27. Colombo M, Fernández I, Abdurakhmanov D, et al. Treatment of Hepatitis C Genotype 1 Patients with Severe Fibrosis or Compensated Cirrhosis: The International Telaprevir Early Access Program (EAP). AASLD 2012. Abstract LB 15.
28. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
29. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
30. Gilead Sciences Press Releases May 2, 2013
31. Poordad F, Fried MW, Zeuzem S, et al. Efficacy and tolerability of TMC435 150 mg once daily with peginterferon α-2a and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials). AASLD 2012. Abstract 83
32. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. EASL 2013. Abstract 1425.
33. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment- naive patients: results from QUEST-2, a phase III trial. EASL2013. Abstract 1413.
34. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of viral load through 4 weeks post-treatment results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections 2013. Abstract 155LB.
35. Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial. EASL 2013. Abstract 1416.
36. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.